[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644385":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":42,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":20,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"combined therapy","EXPERIMENTAL","atorvastatin 20mg qd , N-acetyl-L-cysteine (NAC) 400mg tid, and romiplostim",[13],"Drug: atorvastatin, NAC, and romiplostim",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","atorvastatin, NAC, and romiplostim","From Week 1 to Week 24, atorvastatin and NAC was administrated as the dose of 20mg qd and 400mg tid,respectively, and were discontinued at the end of Week 24. For romiplostim, the initial dose was 3 μg\u002Fkg per week. The weekly dose was adjusted based on platelet counts, with a maximum dose of 10 μg\u002Fkg per week, to maintain platelet levels within the range of 100-200×10⁹\u002FL during the initial 24-week period. From Week 25 to Week 35, romiplostim was gradually tapered and discontinued with the goal of maintaining a platelet count ≥30×10⁹\u002FL and no less than twice the baseline level. After all medications (including atorvastatin, NAC, and romiplostim) were discontinued (no later than Week 36), patients were followed up for an additional 24 weeks to evaluate the sustained response rate at 24 weeks post-treatment cessation.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Fu Haixia, Dr.","CONTACT","+861088326002","fuhaixia_210@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Xiaohui Zhang, Dr.","861088326001","zhangxh@bjmu.edu.cn",[32],{"facility":5,"status":20,"city":33,"state":20,"zip":20,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":20},"Beijing","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Fu Haixia","Chief physician","100644385","atorvastatin-combined-with-nac-plus-romiplostim-for-management-of-itp-100644385",false,"NCT07662525","Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP","Atorvastatin Combined With N-Acetyl-L-Cysteine Plus Romiplostim for Management of Steroid-Resistant\u002FRelapsed Immune Thrombocytopenia","Inclusion Criteria:\n\n* Diagnosed with primary ITP;\n* Aged ≥18 years;\n* Patients with treatment failure or relapse after first-line corticosteriod therapy for ITP;\n* Platelet count \\\u003C30×10⁹\u002FL.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant;\n* Presence of active malignant tumors;\n* Active HBV, HCV or HIV infection;\n* Active infection requiring systematic treatment;\n* Leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis or other hematological disorders that may cause thrombocytopenia;\n* History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure;\n* AST \\> 2 times the upper limit of normal (ULN), ALT \\> 2×ULN, or TBIL ≥ 1.5×ULN;\n* eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m²;\n* Any other subjects deemed ineligible for enrollment by the investigator.","ALL","18 Years",{"count":56,"type":57},50,"ESTIMATED","INTERVENTIONAL",[60],"NA","This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.",[63],"Immune Thrombocytopenic Purpura",[65,66,67,68,69],"immune thrombocytopenia","atorvastatin","N-acetyl-L-cysteine","romiplostim","sustained response off-treatment","NOT_YET_RECRUITING","2026-06-19",{"date":73,"type":74},"2026-06-23","ACTUAL",{"date":76,"type":57},"2026-06-01",{"date":78,"type":57},"2028-12-30",{"name":5,"class":6},1]